Iovance Biotherapeutics (IOVA) Net Cash Flow (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Net Cash Flow of $33.6 million for Q1 2026, down 39.39% year-over-year from $55.5 million in Q1 2025, and up 666.04% quarter-over-quarter from $4.4 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Net Cash Flow (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Net Cash Flow for 15 consecutive years, with $33.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 39.39% year-over-year to $33.6 million; the TTM figure through Mar 2026 stood at $24.0 million (down 35.06% YoY), while the FY2025 annual figure was $45.9 million, up 178.11% from the prior year.
- Net Cash Flow climbed to $33.6 million in Q1 2026 per IOVA's latest filing, from $4.4 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $311.8 million in Q1 2023 and bottomed at -$249.7 million in Q2 2023.
- Historically, Net Cash Flow has averaged $7.1 million across 5 years, with a median of $14.1 million in 2022.
- On a YoY basis, Net Cash Flow climbed as much as 2106.16% in 2023 and fell as far as 1654.74% in 2023.
- Iovance Biotherapeutics' Net Cash Flow stood at $113.4 million in 2022, then tumbled by 237.48% to -$155.9 million in 2023, then soared by 69.64% to -$47.3 million in 2024, then soared by 109.28% to $4.4 million in 2025, then surged by 666.04% to $33.6 million in 2026.
- Business Quant data shows IOVA's Net Cash Flow at $33.6 million in Q1 2026, $4.4 million in Q4 2025, and $26.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | -85.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -85.58 Mn |
| Jun 30, 2026 | -85.58 Mn |
| Mar 31, 2026 | 33.63 Mn |
| Mar 31, 2026 | 33.63 Mn |
| Dec 31, 2025 | 4.39 Mn |
| Dec 31, 2025 | 4.39 Mn |
| Sep 30, 2025 | 26.33 Mn |
| Sep 30, 2025 | 26.33 Mn |
| Jun 30, 2025 | -40.33 Mn |
| Jun 30, 2025 | -40.33 Mn |
| Mar 31, 2025 | 55.49 Mn |
| Mar 31, 2025 | 55.49 Mn |
| Dec 31, 2024 | -47.31 Mn |
| Dec 31, 2024 | -47.31 Mn |
| Sep 30, 2024 | -65.82 Mn |
| Sep 30, 2024 | -65.82 Mn |
| Jun 30, 2024 | 94.62 Mn |
| Jun 30, 2024 | 94.62 Mn |
| Mar 31, 2024 | -40.21 Mn |
| Mar 31, 2024 | -40.21 Mn |